Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113644 | 0.86 | OPRM1 (0.50) | MEN1KMT2ACYP2D6ACHETSHR | |
| SCHEMBL1488930 | 0.76 | HTR2C (0.48) | GAAMEN1KMT2AOPRK1ALDH1A1 | |
| SCHEMBL18075896 | 0.72 | SIGMAR1 (0.48) | MEN1KMT2ATSHROPRM1OPRD1 | |
| SCHEMBL13864847 | 0.71 | OPRL1 (0.48) | MEN1KMT2ACYP2D6ACHECHRM2 | |
| SCHEMBL12233131 | 0.71 | CHRNA7 (0.33) | — | |
| SCHEMBL17101341 | 0.69 | SIGMAR1 (0.45) | MEN1KMT2ATSHROPRM1OPRD1 | |
| SCHEMBL29597582 | 0.68 | GAA (0.65) | GAAMEN1KMT2ACYP2D6ACHE | |
| SCHEMBL27010297 | 0.67 | GAA (0.59) | GAAMEN1KMT2ACYP2D6ACHE | |
| SCHEMBL22829822 | 0.67 | GAA (0.63) | GAAMEN1KMT2ACYP2D6ACHE | |
| SCHEMBL19464108 | 0.67 | GAA (0.63) | GAAMEN1KMT2ACYP2D6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8362002-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | GAA 1549/4885MEN1 581/4885KMT2A 1761/4885 |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | GAA 1407/4885MEN1 565/4885KMT2A 1789/4885 |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | GAA 1549/4885MEN1 581/4885KMT2A 1761/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | GAA 2446/4885MEN1 872/4885KMT2A 885/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | GAA 1845/4885MEN1 1722/4885KMT2A 1162/4885 |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | GAA 607/4885MEN1 164/4885KMT2A 1187/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | GAA 1182/4885MEN1 399/4885KMT2A 1630/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | GAA 2414/4885MEN1 425/4885KMT2A 669/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | GAA 1407/4885MEN1 565/4885KMT2A 1789/4885 |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | GAA 607/4885MEN1 164/4885KMT2A 1187/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | GAA 1407/4885MEN1 565/4885KMT2A 1789/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | GAA 1407/4885MEN1 565/4885KMT2A 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.